BMS-962212

BMS‐962212 is a small molecule antithrombotic drug developed as a direct, reversible and selective inhibitor of factor XIa (FXIa), an enzyme involved in the intrinsic pathway of blood coagulation. It is administered intravenously and has demonstrated significant antithrombotic activity with minimal impact on hemostasis in preclinical models. The drug exhibits fast onset of pharmacodynamic response and rapid elimination. Its mechanism targets FXIa to reduce thrombosis risk while aiming to preserve normal hemostasis more effectively than traditional anticoagulants. Developed by Bristol Myers Squibb for acute care use in hospital settings, it has reached up to Phase I/II clinical trials for thrombosis[1][6][4][5].

Other names

4-[[(1S)-2-[(E)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro‑1H‑isoquinoline‑1-carbonyl]amino]benzoic acidBENZOIC ACID, 4‑((((1S)‑2‑((2E)‑3-(3-chloro‑2-fluoro‑6-(1H-tetrazol–1–yl)phenyl)acryloyl)–5–(4-methyl–2–oxopiperazin–1–yl)–1,2,3,4-tetrahydroisoquinoline—carboxamido))benzoic acid